661 related articles for article (PubMed ID: 27832783)
21. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
22. LncRNA LINC00152 Increases the Aggressiveness of Human Retinoblastoma and Enhances Carboplatin and Adriamycin Resistance by Regulating MiR-613/Yes-Associated Protein 1 (YAP1) Axis.
Wang Y; Xin D; Zhou L
Med Sci Monit; 2020 Jun; 26():e920886. PubMed ID: 32541644
[TBL] [Abstract][Full Text] [Related]
23. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
[TBL] [Abstract][Full Text] [Related]
25. Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma.
Kang W; Tong JH; Lung RW; Dong Y; Zhao J; Liang Q; Zhang L; Pan Y; Yang W; Pang JC; Cheng AS; Yu J; To KF
Mol Cancer; 2015 Feb; 14():52. PubMed ID: 25743273
[TBL] [Abstract][Full Text] [Related]
26. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
27. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.
Li C; Zhao L; Chen Y; He T; Chen X; Mao J; Li C; Lyu J; Meng QH
BMC Cancer; 2016 Aug; 16():605. PubMed ID: 27495250
[TBL] [Abstract][Full Text] [Related]
29. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1.
Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y
Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984
[No Abstract] [Full Text] [Related]
30. miR-424-5p Regulates Hepatoma Cell Proliferation and Apoptosis.
Piao L; Wang F; Wang Y; Yang Z; Li Q; Cui L; Yu Q
Cancer Biother Radiopharm; 2019 Apr; 34(3):196-202. PubMed ID: 30676784
[TBL] [Abstract][Full Text] [Related]
31. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
32. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract][Full Text] [Related]
33. MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
Yang F; Luo LJ; Zhang L; Wang DD; Yang SJ; Ding L; Li J; Chen D; Ma R; Wu JZ; Tang JH
Gene; 2017 Feb; 600():21-28. PubMed ID: 27913185
[TBL] [Abstract][Full Text] [Related]
34. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
35. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
Wang X; Yang B; Ma B
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
[TBL] [Abstract][Full Text] [Related]
36. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
37. miR-138 suppresses the proliferation of oral squamous cell carcinoma cells by targeting Yes-associated protein 1.
Xu R; Zeng G; Gao J; Ren Y; Zhang Z; Zhang Q; Zhao J; Tao H; Li D
Oncol Rep; 2015 Oct; 34(4):2171-8. PubMed ID: 26239136
[TBL] [Abstract][Full Text] [Related]
38. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
40. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]